S'abonner

Association of Atrial Septal Defects and Bronchopulmonary Dysplasia in Premature Infants - 23/10/18

Doi : 10.1016/j.jpeds.2018.07.024 
Karan R. Kumar, MD 1, 2, David A. Clark 1, Evan M. Kim 1, Jasmine D. Perry 1, Kaylyn Wright 1, Sheikisha A. Thomas 1, Elizabeth J. Thompson, MD 2, Rachel G. Greenberg, MD, MB, MHS 1, 2, P. Brian Smith, MD, MPH, MHS 1, 2, Daniel K. Benjamin, MD, PhD, MPH 1, 2, Matthew M. Laughon, MD, MPH 3, Reese H. Clark, MD 4, Christoph P. Hornik, MD, MPH 1, 2, *
1 Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC 
2 Department of Pediatrics, Duke University School of Medicine, Durham, NC 
3 Department of Pediatrics, The University of North Carolina at Chapel Hill, Chapel Hill, NC 
4 Pediatrix-Obstetrix Center for Research and Education, Sunrise, FL 

*Reprint requests: Christoph P. Hornik, MD, MPH, Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715.Duke Clinical Research InstitutePO Box 17969DurhamNC27715

Abstract

Objective

To evaluate the association between the presence of an atrial septal defect (ASD) and the odds of developing bronchopulmonary dysplasia (BPD) in premature infants.

Study design

We identified a cohort of infants that underwent at least one echocardiogram assessment, birth weight 501-1249 g, and gestational age 23-30 weeks discharged from the neonatal intensive care unit from 2004 to 2016. We used a BPD risk estimator to calculate the predicted risk of developing BPD at 6 postnatal ages within the first 28 days of life. We examined the association between the presence of an ASD and the development of BPD using 2 multivariable logistic regression models for each BPD risk severity on each postnatal day. The first model adjusted for predicted BPD risk and the second added therapeutic interventions for BPD.

Results

Of 20 496 infants from 228 NICUs who met inclusion criteria, 8892 (43%) were diagnosed with BPD and 1314 (6%) had an ASD. BPD was present in 48% of infants with an ASD and 43% of infants without an ASD. In infants with an ASD, the OR of developing BPD was higher after adjusting for predicted risk of BPD plus therapeutic interventions, regardless of postnatal age or predicted BPD risk severity.

Conclusions

The presence of an ASD was associated with an increased odds of BPD in this cohort. Future trials should consider ASD as a potentially modifiable risk factor in this vulnerable population.

Le texte complet de cet article est disponible en PDF.

Keywords : chronic lung disease, congenital heart disease, pulmonary hypertension

Abbreviations : ASD, BPD, CHD, FiO2, NICHD, NICU, PDA, PH


Plan


 Funded, in part, by the National Institute of Child Health and Human Development (NICHD) (5R25HD076475-05). K.K. receives research support from the National Institutes of Health (NIH) (5T32HD043029-15 and 4T32HD043029-14). E.T. receives research support from the NIH (4T32HD043029-14). R.G. receives research support from the NICHD (HHSN275201000003I), National Institute of Allergy and Infectious Diseases (NIAID) (HHSN272201300017I), and Food and Drug Administration (FDA) (HHSF223201610082C). P.S. receives research support from the NIH (1R21HD080606-01A1), NICHD (HHSN275201000003I), ECHO Program (1U2COD023375-01), and FDA (1R18FD005292-01); he also receives research support from Industry for Neonatal and Pediatric Drug Development (coi.jsp). D.B. receives support from the NIH (2K24HD058735-06), NICHD (HHSN275201000003I), NIAID (HHSN272201500006I), ECHO Program (1U2COD023375-01), and National Center for Advancing Translational Sciences (NCATS) (1U24TR001608-01); he also receives research support from Cempra Pharmaceuticals (subaward to HHSO100201300009C) and industry for neonatal and pediatric drug development (coi.jsp). M.L. receives research support from the FDA (R01FD005101), National Heart, Lung, and Blood Institute (NHLBI) (R34HL124038), ECHO Program (U2COD023375), NICHD (U10HD040492), and the U.S. government for his work in neonatal clinical pharmacology (Government Contract HHSN267200700051C). C.H. receives research support from the NICHD (1K23HD090239) and the U.S. government for his work in pediatric and neonatal clinical pharmacology (Government Contract HHSN267200700051C); he also receives research support from industry for pediatric drug development (conflict-of-interest/). The other authors declare no conflicts of interest.


© 2018  Elsevier Inc. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 202

P. 56 - novembre 2018 Retour au numéro
Article précédent Article précédent
  • Relationship of Patent Ductus Arteriosus Size to Echocardiographic Markers of Shunt Volume
  • Fernando de Freitas Martins, Daniel Ibarra Rios, Maura Helena F. Resende, Henna Javed, Dany Weisz, Amish Jain, Jose Maria de Andrade Lopes, Patrick J. McNamara
| Article suivant Article suivant
  • Executive Function and Psychosocial Quality of Life in School Age Children with Congenital Heart Disease
  • Jacqueline H. Sanz, Jichuan Wang, Madison M. Berl, Anna C. Armour, Yao I. Cheng, Mary T. Donofrio

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.